Tag: COVID-19
The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal
Clinical trials of disease stages in COVID 19: complicated and often misinterpreted
As of 2020年7月28日, 1840 clinical trials were registered globally, with 1001 clinical trials recruiting patients for COVID-19 management.1 Despite this large number, only 30 trials have been published as peer-reviewed or preprint publications.2 Media reports and prepublications on medRxiv and bioRxiv represent the most frequent mechanism for data sharing, with wide public reach and usually with little detail. However, … Continued
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19
As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for accelerated development is the evaluation of drug combinations in the absence of prior monotherapy data. This approach is appealing for a number of reasons. First, combining two or … Continued
Certara Announces First Enrollee in International Registry to Assess Preventative Therapies in Healthcare Workers Exposed to COVID-19
Real-World Data on 10,000 Healthcare Workers to Inform COVID-19 Prevention Policies PRINCETON, N.J.—2020年8月13日. Certara®, the global leader in biosimulation, has launched an international registry of healthcare workers to collect information on risk factors for developing COVID-19 and the use of preventative therapies. The International Registry of Healthcare Workers Exposed to COVID-19 (UNITY Global) … Continued
Everyone is hoping for silver bullet for COVID-19, but N.J.’s biopharma experts know collaboration could wind up key
Addressing the COVID-19 challenge with computer modeling & simulation
Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development (MIDD)…
Go to war with the army you have: Until there’s a vaccine, a cocktail can fight Covid-19
A successful cocktail would also serve us in the long-run to treat the impacts of Covid-19 and keep those who are most vulnerable, the elderly and those with pre-existing conditions, more resilient against serious illness or death….
Certara Launches COVID-19 Clinical Outcomes Database
Research Database to Quantify Impact of Potential COVID-19 Treatments,
with Results from Over 500 Clinical Trials and Observational Studies Over the Next Three Months
Model-based meta-analysis for comparative efficacy and safety of therapeutics for COVID-19
Certara is launching the COVID-19 Clinical Outcomes Database, funded by the COVID-19 Therapeutics Accelerator. The Database includes observational studies and clinical trials with more than 10 patients that evaluate specific treatment options to improve disease outcome. It captures all patient characteristics, safety and efficacy outcomes, biomarkers and viral load data. The database also includes studies (>100 patients) that evaluate patient characteristics stratified by disease outcome such as death, or progression to severe or critical disease and studies (>10 patients) that report the time course of viral load, vital signs, and biomarkers.
